Antimicrobial Agents and Chemotherapy最新文献

{"title":"Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for <i>Candida</i> infections.","authors":"Elodie Matusik, Olivia Vassal, Anne Conrad, Tristan Ferry, Aurélien Millet, Damien Dupont, Lola Grandjean, Jérôme Guitton, Sandrine Roux, Anne-Lise Bienvenu, Julien Bohé, Arnaud Friggeri, Sylvain Goutelle","doi":"10.1128/aac.00991-24","DOIUrl":"10.1128/aac.00991-24","url":null,"abstract":"<p><p>Large pharmacokinetic (PK) variability of fluconazole has been reported in critically ill patients, but the implications for fluconazole dosing remain unclear. The objectives of this study were to evaluate the population PK of fluconazole and identify appropriate dosage regimens by simulations. This was a retrospective analysis of fluconazole PK data from patients hospitalized in critical care and infectious disease departments. Both parametric and nonparametric population approaches were used. Various loading and maintenance fluconazole doses were evaluated by simulations, with computation of the probabilities of PK/pharmacodynamic (PD) target attainment (PTA) and cumulative fractions of response (CFR) based on international and local minimum inhibitory concentration (MIC) distributions of <i>Candida</i> sp. Data from 36 critically ill patients and 16 non-critically ill patients were available for model building (<i>n</i> = 202 concentrations). The final model adequately described the data, including the external data set (13 patients). After 24 h of therapy, 65% and 74% of patients had trough and area under the concentration-time curve values below the usual targets. Standard dosages were associated with low PTA for MIC >1 mg/L at 24 h. Higher loading doses administered two times daily improved PTA. CFR were >90% for <i>C. albicans</i> with standard dosages, while they were very low for <i>C. glabrata</i>, even with high dosages. <i>Candida</i> species and associated MIC distributions strongly influence fluconazole dosage requirements. Higher loading doses may be necessary for the achievement of PK/PD targets up to MIC breakpoints. The use of fluconazole for invasive <i>C. glabrata</i> infection should be discouraged because of poor PK/PD target attainment.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0099124"},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High frequency of acquired virulence factors in carbapenemase-producing <i>Klebsiella pneumoniae</i> isolates from a large German university hospital, 2013-2021.","authors":"Janko Sattler, Christoph M Ernst, Janine Zweigner, Axel Hamprecht","doi":"10.1128/aac.00602-24","DOIUrl":"10.1128/aac.00602-24","url":null,"abstract":"<p><p>Carbapenemase-producing <i>Klebsiella pneumoniae</i> (CP-Kp) isolates are a public health concern as they can cause severe hospital-acquired infections that are difficult to treat. It has recently been shown that CP-Kp can take up virulence factors from hypervirulent <i>K. pneumoniae</i> lineages. In this study, 109 clinical CP-Kp isolates from the University Hospital Cologne were examined for the presence of acquired virulence factors using whole-genome sequencing and phenotypic tests, and results were linked to clinical data. The virulence factor <i>iuc</i> was present in 18/109 of the CP-Kp isolates. Other acquired virulence factors, such as <i>ybt</i>, <i>cbt</i>, <i>iro</i>, <i>rmpA/rmpA2</i>, <i>peg-344</i>, and hypervirulence-associated capsule types were detected in various combinations among these isolates. The <i>iuc</i>-positive isolates produced OXA-232 (<i>n</i> = 7), OXA-48 (<i>n</i> = 6), OXA-48+NDM (<i>n</i> = 3), NDM, and KPC (each <i>n</i> = 1), and 7/18 isolates were resistant to ceftazidime-avibactam, colistin, and/or cefiderocol. Four isolates carried hybrid plasmids that harbored acquired virulence factors alongside the carbapenemase genes <i>bla</i>_NDM-1/5 or <i>bla</i>_OXA-48. In 15/18 patients, <i>iuc</i>-positive CP-Kp were isolated from a clinically manifest infection site. Among these, four patients had osteomyelitis, and four patients died from pneumonia with OXA-232-producing ST231 isolates, three of them as part of an outbreak. In conclusion, acquired virulence factors are frequently detected in various combinations in carbapenemase-producing <i>K. pneumoniae</i> isolates in Germany, warranting continuous monitoring of infections caused by these strains.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0060224"},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of porin deficiency on the synergistic potential of colistin in combination with β-lactam/β-lactamase inhibitors against ESBL- and carbapenemase-producing <i>Klebsiella pneumoniae</i>.","authors":"Lisa Allander, Karin Vickberg, Elin Fermér, Thomas Söderhäll, Linus Sandegren, Pernilla Lagerbäck, Thomas Tängdén","doi":"10.1128/aac.00762-24","DOIUrl":"10.1128/aac.00762-24","url":null,"abstract":"<p><p>Combinations of colistin and β-lactam/β-lactamase inhibitors (BLBLIs) have shown <i>in vitro</i> synergy against β-lactamase-producing strains. However, data are limited and conflicting, potentially attributed to variations among the examined strains. This study investigated whether loss of porins OmpK35 and OmpK36 impacts the synergistic potential of colistin in combination with ceftazidime-avibactam or meropenem-avibactam against β-lactamase-producing <i>Klebsiella pneumoniae</i>. Genetically modified strains were constructed by introducing <i>bla</i>_CTX-M-15, <i>bla</i>_KPC-2, and <i>bla</i>_OXA-48 chromosomally into <i>K. pneumoniae</i> ATCC 35657, in which the major porin-encoding genes (<i>ompK35</i>, <i>ompK36</i>) were either intact or knocked out. The <i>in vitro</i> activity of colistin in combination with ceftazidime-avibactam or meropenem-avibactam was evaluated by time-lapse microscopy screening and in static time-kill experiments. The deletion of porins in the β-lactamase-producing strains resulted in 2- to 128-fold increases in MICs for the β-lactams and BLBLIs. The activity of avibactam was concentration-dependent, and 4- to 16-fold higher concentrations were required to achieve similar inhibition of the β-lactamases in strains with porin loss. In the screening, synergy was observed for colistin and ceftazidime-avibactam against the CTX-M-15-producing strains and colistin and meropenem-avibactam against the KPC-2- and OXA-48-producing strains. The combination effects were less pronounced in the time-kill experiments, where synergy was rarely detected. No apparent associations were found between the loss of OmpK35 and OmpK36 and combination effects with colistin and BLBLIs, indicating that additional factors determine the synergistic potential of such combinations.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0076224"},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.","authors":"Tania Blanco-Martín, Inmaculada López-Hernández, Belén Aracil, Lucía González-Pinto, Pablo Aja-Macaya, Isaac Alonso-García, Salud Rodríguez-Pallares, Lucía Sánchez-Peña, Michelle Outeda-García, María Pérez-Vázquez, Juan Carlos Vázquez-Ucha, Alejandro Beceiro, Álvaro Pascual, Germán Bou, Lorena López-Cerero, Jesús Oteo-Iglesias, Jorge Arca-Suárez","doi":"10.1128/aac.00924-24","DOIUrl":"10.1128/aac.00924-24","url":null,"abstract":"<p><p>We aimed to investigate the activity of and mechanisms of resistance to cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations in a nationwide collection of double-carbapenemase-producing Enterobacterales. In all, 57 clinical isolates co-producing two carbapenemases collected from Spanish hospitals during the period 2017-2022 were analyzed. Minimum inhibitory concentration (MIC) values for ceftazidime, ceftazidime/avibactam, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, cefiderocol, cefepime, cefepime/taniborbactam, cefepime/zidebactam, cefepime/nacubactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, meropenem/xeruborbactam, and meropenem/ANT3310 were determined by reference broth microdilution. Genetic drivers of resistance were analyzed by whole-genome sequencing (WGS). The collection covered nine carbapenemase associations: VIM + OXA-48 (21/57), NDM + OXA-48 (11/57), KPC + VIM (10/57), KPC + OXA-48 (6/57), IMP + OXA-48 (3/57), NDM + KPC (2/57), NDM + VIM (2/57), NDM + GES (1/57), and KPC + IMP (1/57). Ceftazidime/avibactam, imipenem/relebactam, and meropenem/vaborbactam were the least active options. Aztreonam/avibactam and aztreonam/nacubactam were active against the whole collection and yielded MIC₅₀/MIC₉₀ values of ≤0.25/0.5 mg/L and 1/2 mg/L, respectively. Cefepime/zidebactam (56/57 susceptible), meropenem/xeruborbactam (56/57 susceptible), cefepime/nacubactam (55/57 susceptible), and cefiderocol (53/57 susceptible) were also highly active, with MIC₅₀/MIC₉₀ values ranging from ≤0.25-2 mg/L to 2-4 mg/L, respectively. Meropenem/ANT3310 (MIC₅₀/MIC₉₀ = 0.5/≥64 mg/L; 47/57 susceptible) and cefepime/taniborbactam (MIC₅₀/MIC₉₀ = 0.5/16 mg/L; 44/57 susceptible) also retained high levels of activity, although they were affected by NDM-type enzymes in combination with porin deficiency. Our findings highlight that cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, nacubactam, taniborbactam, zidebactam, xeruborbactam, and ANT3310 show promising activity against double-carbapenemase-producing Enterobacterales.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0092424"},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic drug monitoring of linezolid in Chinese premature neonates: a population pharmacokinetic analysis and dosage optimization.","authors":"Lu-Fen Duan, Jing-Jing Li, Li-Rong Shen, Xiang-Long Chen, Yan-Xia Yu, Zu-Ming Yang, Qian Zhang, Yan Cai, Jia-Hui Li, Juan Wu, Han-Zhen Zhao, Jin-Hui Xu, Zong-Tai Feng, Lian Tang","doi":"10.1128/aac.01148-24","DOIUrl":"10.1128/aac.01148-24","url":null,"abstract":"<p><p>This study aimed to develop a pharmacokinetic model of linezolid in premature neonates and evaluate and optimize the administration regimen. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to detect the blood concentration data of 54 premature neonates after intravenous administration of linezolid, and the relevant clinical data were collected. The population pharmacokinetic (PPK) model was established by nonlinear mixed effects modeling. Based on the final model parameters, the optimal administration regimen of linezolid in premature neonates with different body surface areas (BSA) was simulated and evaluated. The pharmacokinetic properties of linezolid in premature neonates are best described by a single-compartment model with primary elimination. The population typical values for apparent volume of distribution and clearance were 0.783 L and 0.154 L/h, respectively. BSA was a statistically significant covariate with clearance (CL) and volume of distribution (V_d). Monte Carlo simulations showed that the optimal administration regimen for linezolid in premature neonates was 6 mg/kg q8h for BSA 0.11 m², 7 mg/kg q8h for BSA 0.13 m², and 9 mg/kg q8h for BSA 0.15 m² with minimum inhibitory concentration (MIC) ≤1 mg/L, 7 mg/kg q8h for BSA 0.11 m², 8 mg/kg q8h for BSA 0.13 m², and 10 mg/kg q8h for BSA 0.15 m² with MIC = 2 mg/L. A pharmacokinetic model was developed to predict the blood concentration on linezolid in premature neonates. Based on this model, the optimal administration regimen of linezolid in premature neonates needs to be individualized according to different BSA levels.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0114824"},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Naamidine A reveals a promising zinc-binding strategy for topical antifungal therapy.","authors":"Emily Puumala, Sunna Nabeela, Christopher C Thornburg, Tanja Grkovic, Priya Uppuluri, Luke Whitesell, Barry R O'Keefe, Nicole Robbins, Leah E Cowen","doi":"10.1128/aac.01194-24","DOIUrl":"10.1128/aac.01194-24","url":null,"abstract":"<p><p>Fungal disease affects over a billion people worldwide. Naamidine A inhibits the growth of diverse fungal pathogens through an unknown mechanism. Here, we show that the supplementation of medium with excess zinc abolishes the antifungal activity of naamidine A. Furthermore, we highlight that naamidine A has <i>in vitro</i> activity against terbinafine-resistant <i>Trichophyton spp</i>. and <i>in vivo</i> efficacy in a mouse model of dermatomycosis caused by <i>T. mentagrophytes,</i> highlighting its therapeutic potential as a topical treatment.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0119424"},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral oxaborole MRX-5 exhibits efficacy against pulmonary <i>Mycobacterium abscessus</i> in mouse.","authors":"Binayak Rimal, Ruth A Howe, Chandra M Panthi, Wen Wang, Gyanu Lamichhane","doi":"10.1128/aac.01351-24","DOIUrl":"10.1128/aac.01351-24","url":null,"abstract":"<p><p><i>Mycobacterium abscessus (Mab</i>) is an opportunistic pathogen common in patients with lung comorbidities and immunosuppression. There are no FDA-approved treatments, and current treatment has a failure rate exceeding 50%. The intravenous oxaborole MRX-6038 is active against <i>Mab</i>. This study evaluated MRX-5, the oral prodrug, against five <i>Mab</i> isolates in a mouse lung infection model. MRX-5 showed dose-dependent efficacy, with 15 and 45 mg/kg doses comparable to the standard of care, supporting progression to clinical trial.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0135124"},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum for Abd Algaffar et al., \"Development and Validation of an <i>In Vitro</i> Resazurin-Based Susceptibility Assay against <i>Madurella mycetomatis</i>\".","authors":"S O Abd Algaffar, A Verbon, W W J van de Sande, S A Khalid","doi":"10.1128/aac.00149-24","DOIUrl":"10.1128/aac.00149-24","url":null,"abstract":"","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0014924"},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of obesity on clinical outcomes of methicillin-susceptible <i>Staphylococcus aureus</i> bloodstream infections.","authors":"Anthony S Wasielewski, Anthony M Casapao, Christopher A Jankowski, Carmen L Isache, Malleswari Ravi, Ashlan J Kunz Coyne","doi":"10.1128/aac.00752-24","DOIUrl":"10.1128/aac.00752-24","url":null,"abstract":"<p><p>Obesity affects over one-third of U.S. adults and complicates the treatment of methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA) bloodstream infections (BSI). A study at the University of Florida Health Centers compared clinical outcomes between 233 obese and non-obese patients receiving cefazolin for MSSA BSI. No significant differences were found in clinical success (81.9% vs 82.7%), mortality (7.2% vs 5.3%), or adverse events (3.6% vs 3.3%). However, obese patients took longer to clear blood cultures (4.62 vs 4.01 days, <i>P</i> = 0.017).</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0075224"},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible <i>Staphylococcus aureus</i> in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection.","authors":"Lina P Carvajal, Sandra Rincon, Sara I Gomez Villegas, J Manuel Matiz-Gonzalez, Karen Ordoñez, Alejandra Santamaria, Leonardo Ospina Navarro, Jaime Beltran, Fredy Guevara, Yardany R Mendez, Soraya Salcedo, Alexandra Porras, Albert Valencia-Moreno, Haley Greenia, Alexander Deyanov, Rodrigo Baptista, Vincent H Tam, Diana Panesso, Truc T Tran, William R Miller, Cesar A Arias, Jinnethe Reyes","doi":"10.1128/aac.00898-24","DOIUrl":"10.1128/aac.00898-24","url":null,"abstract":"<p><p>The cefazolin inoculum effect (CzIE) has been associated with poor clinical outcomes in patients with methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA) infections. We aimed to investigate the point prevalence of the CzIE among nasal colonizing MSSA isolates from ICU patients in a multicenter study in Colombia (2019-2023). Patients underwent nasal swabs to assess for <i>S. aureus</i> colonization on admission to the ICU, and some individuals had follow-up swabs. We performed cefazolin MIC by broth microdilution using standard and high inoculum and developed a modified nitrocefin-based rapid test to detect the CzIE. Whole-genome sequencing was carried out to characterize BlaZ types and allotypes, phylogenomics, and Agr-typing. A total of 352 patients were included; 46/352 (13%) patients were colonized with <i>S. aureus</i> and 22% (10/46) and 78% (36/46) with MRSA and MSSA, respectively. Among 36 patients who contributed with 43 MSSA colonizing isolates, 21/36 (58%) had MSSA exhibiting the CzIE. BlaZ type A and BlaZ-2 were the predominant type and allotype in 56% and 52%, respectively. MSSA belonging to CC30 were highly associated with the CzIE, and single-nucleotide polymorphism (SNP) analyses supported possible transmission of MSSA exhibiting the CzIE among some patients of the same unit. The modified nitrocefin rapid test had 100%, 94.4%, and 97.7% sensitivity, specificity, and accuracy, respectively. We found a high point prevalence of the CzIE in MSSA colonizing the nares of critically ill patients in Colombia. A modified rapid test was highly accurate in detecting the CzIE in this patient population.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0089824"},"PeriodicalIF":4.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}